Detalhe da pesquisa
1.
ACSL4 is a predictive biomarker of sorafenib sensitivity in hepatocellular carcinoma.
Acta Pharmacol Sin
; 42(1): 160-170, 2021 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-32541921
2.
Histone deacetylases up-regulate C/EBPα expression through reduction of miR-124-3p and miR-25 in hepatocellular carcinoma.
Biochem Biophys Res Commun
; 514(3): 1009-1016, 2019 06 30.
Artigo
Inglês
| MEDLINE | ID: mdl-31092334
3.
Simultaneous treatment with sorafenib and glucose restriction inhibits hepatocellular carcinoma in vitro and in vivo by impairing SIAH1-mediated mitophagy.
Exp Mol Med
; 54(11): 2007-2021, 2022 11.
Artigo
Inglês
| MEDLINE | ID: mdl-36385558
4.
Identification of Key Genes in Purine Metabolism as Prognostic Biomarker for Hepatocellular Carcinoma.
Front Oncol
; 10: 583053, 2020.
Artigo
Inglês
| MEDLINE | ID: mdl-33520699